uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
RBC Capital on uniQure BV (QURE): 'Brain Safety Signal Unfortunate, But Stock Reaction Overdone'
August 8, 2022 12:59 PM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $53.00 price target on uniQure BV (NASDAQ: QURE)
The analyst comments "Huntington's brain safety signal is unfortunate as it will delay the program, formal FDA clinical hold is possible and one patient has... More
Cowen on uniQure BV (QURE): 'We are hopeful the risk is manageable'
August 8, 2022 12:59 PM EDTCowen analyst Joseph Thome reiterated an Outperform rating on uniQure BV (NASDAQ: QURE).
The analyst comments "While the news is unfortunate and warrants additional investigation, we note that the U.S. data update remains on track for Q2:23 and a total of... More
Goldman Sachs Reiterates Buy Rating on uniQure BV (QURE)
August 8, 2022 12:57 PM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $51.00 price target on uniQure BV (NASDAQ: QURE).
The analyst comments "QURE released 2Q EPS and announced the postponement of procedures in the higher-dose cohort (6x1013vg) of the Ph1/2 US and Ph1b/2 EU studies of gene therapy AMT-130 in Huntingtons disease due to suspected unexpected... More
Credit Suisse Reiterates Outperform Rating on uniQure BV (QURE), 'Catalysts On-Track'
August 8, 2022 12:54 PM EDTCredit Suisse analyst Judah C. Frommer reiterated an Outperform rating and $51.00 price target on uniQure BV (NASDAQ: QURE)
The analyst comments "With 2Q22 earnings QURE disclosed pausing of enrollment in the high-dose cohort of its Ph1/2 AMT-130 (Huntingtons GT) trial following DSMB recommendation tied to 3 suspected unexpected severe adverse... More
uniQure (QURE) Tops Q2 EPS by 16c
August 8, 2022 7:13 AM EDTuniQure (NASDAQ: QURE) reported Q2 EPS of ($0.84), $0.16 better than the analyst estimate of ($1.00). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $9.55 million.
For earnings history and earnings-related data on uniQure (QURE) click here.
... More